Edison Investment Research - Murray International Trust PLC (MYI) Murray International Trust - Continuing to favour emerging markets

Report

Edison Investment Research

Pedro Fonseca

Murray International Trust - Continuing to favour emerging markets

Murray International Trust (MYI) is a well-established investment trust, launched in 1907. Manager Bruce Stout runs a diversified portfolio of global equities and fixed income securities, aiming to achieve long-term capital growth while protecting capital during periods of market weakness, and generate an above-average level of income (the current dividend yield is 4.4%). The majority of the portfolio is invested in emerging markets: regions where the manager finds the most attractive opportunities, and which continue to employ orthodox economic policies, unlike many developed markets.

08/10/2019 10 EN

Underlying

Murray International Trust PLC

Murray International Trust is an investment trust company. Co.'s alternative Investment Fund Manager is Aberdeen Fund Managers limited and the management of portfolio is delegated to Aberdeen Asset Managers Limited.

See profile

GB0006111909 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

Edison Investment Research

Murray International Trust - Attractive offering of income and capital growth

Murray International Trust’s (MYI’s) three managers, Bruce Stout, Martin Connaghan and Samantha Fitzpatrick, have worked closely together since 2001, so it will be business as usual when Stout retires at the end of June. The trust has amassed considerable revenue reserves (equivalent to around one year’s annual dividend) so was able to continue its progressive dividend policy during COVID; MYI returned to a covered dividend in FY22. Despite high inflation preventing real (above inflation) dividend growth in recent years, the trust now has an 18-year record of consecutive annual dividend growth...

January 18, 2024 January 18, 2024 1 EN

Edison Investment Research

Murray International Trust - Business as usual at Murray International

The board of Murray International Trust (MYI) has been planning for manager Bruce Stout’s end-June 2024 retirement for a long time. He and the trust’s other two co-managers, Martin Connaghan and Samantha Fitzpatrick, have worked together for many years and they all share the same investment philosophy, so following Stout’s departure it will be business as usual. MYI returned to a covered dividend in FY22 following a two-year period where the trust’s income was negatively affected by COVID. Although real (above inflation) dividend growth is unlikely in the current high inflation environment, th...

September 12, 2023 September 12, 2023 1 EN

Edison Investment Research

Murray International Trust - Things looking good for MYI’s shareholders

Murray International Trust (MYI) is managed by members of abrdn’s global equity team, Bruce Stout (lead manager), Martin Connaghan and Samantha Fitzpatrick. Things are progressing well for the trust, which meaningfully outperformed its global reference index in FY22. MYI’s income during the period exceeded the managers’ expectations and the proposed annual dividend was c 1.1x covered. Performance has been enhanced by portfolio activity undertaken during the global pandemic, due to successful stock selection and a further asset allocation shift into equities from fixed income securities. The ma...

March 16, 2023 March 16, 2023 1 EN

IP Group - Several potential portfolio catalysts on the horizon

IP Group’s NAV declined by 13% in total return (TR) terms in FY23, affected by continued soft valuations across venture capital (VC) markets, as well as funding delays at some of its holdings. That said, management indicated that many of IP Group’s portfolio companies continued to make strong progress. Its maturing portfolio offers a number of potential NAV triggers and is now available at a wide 59% discount to NAV. We note that, as at end-2023, only 14% of IP Group’s portfolio was valued based on funding rounds completed more than 12 months ago and 46% of its private portfolio was valued by ...

4h / 29m 4h / 29m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

6h / 47m 6h / 47m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

7h / 8m 7h / 8m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Murray International Trust - Continuing to favour emerging markets

Murray International Trust - Attractive offering of income and capital growth

Murray International Trust - Business as usual at Murray International

Murray International Trust - Things looking good for MYI’s shareholders

IP Group - Several potential portfolio catalysts on the horizon

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe